LCM
ALLO icon

Lynx1 Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Lynx1 Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-546,119
Closed -$677K – 24
2025
Q3 		$677K Sell
546,119
-10,510,890
-95% -$12.5M 0.14% 13
2025
Q2 		$12.5M Hold
11,057,009
– – 3.61% 6
2025
Q1 		$16.1M Buy
11,057,009
+182,286
+2% +$344K 5.78% 6
2024
Q4 		$23.2M Buy
10,874,723
+4,672,349
+75% +$11.5M 8.68% 5
2024
Q3 		$17.4M Buy
6,202,374
+3,974,079
+178% +$10.6M 6.15% 6
2024
Q2 		$5.19M Buy
+2,228,295
New +$6.57M 1.87% 7

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Lynx1 Capital Management's ALLO Position: Q4 2025 in Review

Lynx1 Capital Management sold out of Allogene Therapeutics (ALLO) in Q4 2025, closing a stake of 546,119 shares — an estimated $677K sold.

Lynx1 Capital Management first reported a position in ALLO in Q2 2024 and held it in 6 quarters. The position peaked at $23.2M in Q4 2024. 172 funds tracked by Wall St. Rank hold ALLO as of Q4 2025.

  • Lynx1 Capital Management reported no remaining Allogene Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lynx1 Capital Management sold 546,119 Allogene Therapeutics shares in Q4 2025, an estimated $677K.
  • Lynx1 Capital Management first reported a position in Allogene Therapeutics in Q2 2024 and held it in 6 quarters.
  • Lynx1 Capital Management's Allogene Therapeutics position peaked at $23.2M in Q4 2024.
  • 172 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2025.

Based on Lynx1 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.